We are live on ! Find out more

Climb Bio

CLYM

Market cap $589M

10.25 USD

-0.08

0.77%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

10.27

+0.02

0.2%

1 day

-0.77%

5 days

3.74%

1 month

-10.64%

3 months

-15.15%

6 months

15.43%

Year to date

173.33%

1 year

415.08%

5 years

-35.41%

10 years

-35.53%

About: Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Employees: 29

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.3%

Neutral 54.5%

Negative 18.2%

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the first half of 2027 Global Phase 3 trial expected to initiate in 2027 WELLESLEY HILLS, Mass. and BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM, “Climb Bio”) and Beijing Mabworks Biotech Co., Ltd.

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Zacks Investment Research

Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?

Here is how Climb Bio, Inc. (CLYM) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?

Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval

Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug for broader autoimmune indications. CLYM is well-capitalized with $239.2M in cash, providing operational runway into 2H 2028 and enabling progression through key clinical milestones without near-term dilution. CLYM116's modeled quarterly dosing and Budoprutug's CD19 differentiation present compelling product advantages, but both face competitive and execution risks in crowded markets.

Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Investors Business Daily

Biotech Stocks Dive As Top 2% Names Take Hardest Hit

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

Biotech Stocks Dive As Top 2% Names Take Hardest Hit

Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug

Climb Bio NASDAQ: CLYM presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China.

Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug

Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial assessing CLYM116, while revealing updated strategic plans for treating IgA nephropathy, a kidney disease.

Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Investors Business Daily

Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded

Climb Bio reversed course Thursday despite potential "best-in-class" data for its experimental kidney disease treatment.

Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 2027, Phase 3 study initiation in 2027 Company to host R&D Spotlight Webcast today, September 3 at 8:00 a.m. ET WELLESLEY HILLS, Mass.

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

See News Rankings

Price charts implemented using Lightweight Charts™